TMA-2

Discovery

Viktor Bruckner first synthesized TMA-2 in 1933 during chemical research unrelated to psychopharmacology.^[3] Alexander Shulgin independently prepared and tested it in 1962. His 1964 paper was the first scientific report of its effects — describing a mescaline-like experience, but notably lacking in color enhancement and more prone to anxiety.^[4]

Publication and significance

Shulgin's PiHKAL (1991) documented TMA-2 as Entry #158, providing the only published human dose-effect data for the compound.^[3] That entry remained the primary pharmacological reference for decades. TMA-2's principal scientific value is as a structural reference point — the methoxy-substituted anchor of the DOx series.

Prohibition and modern status

The EMCDDA's 2003 risk assessment found no reports of toxic effects or deaths in the EU.^[5] Despite this, an EU Council Decision mandated control measures and criminal sanctions across all member states.^[6] Since then, TMA-2 has appeared sporadically in forensic monitoring in Japan and Europe.^[7]

Structural class

TMA-2 belongs to the DOx series — a family of 2,5-dimethoxyamphetamines within the broader substituted phenethylamine class.^[2] Its molecular formula is C₁₂H₁₉NO₃ (molecular weight 225.28 g/mol).^[8][9]

It shares its backbone with DOM, DOI, and DOB, differing only at the 4-position, where it carries a methoxy group rather than a halogen or methyl substituent.

Mechanism of action

TMA-2 works by activating serotonin receptors in the brain.^[2][10] Despite relatively weak binding, it achieves near-full receptor activation — meaning it needs to occupy only a small fraction of available receptors to produce its full effect.^[2]

Unlike stimulant amphetamines such as amphetamine or MDMA, TMA-2 has almost no effect on dopamine or norepinephrine systems.^[11] Its psychoactive effects come almost entirely from serotonin receptor activation.

Pharmacokinetics

No human pharmacokinetic studies have been published. All timing estimates come from Shulgin's self-experimentation.^[3] In animal models, the body processes TMA-2 mainly by removing its methoxy groups, starting at the 4-position.^[12] A liver enzyme called CYP2D6 handles this step.^[13]

Where it acts

TMA-2 activates serotonin receptors on neurons in the prefrontal cortex, increasing excitatory signaling and disrupting the brain's normal sensory filtering.^[2][10] In mice, blocking these receptors eliminates the compound's behavioral effects entirely.^[10] The stimulation and restlessness users report likely reflects this cortical excitation.

Why it matters

Activating serotonin receptors loosens the brain's reliance on learned predictions, allowing raw sensory information to flow more freely. TMA-2's effects — altered thinking and mild perceptual shifts with muted visuals — suggest it may engage visual processing circuits less strongly than mescaline, despite sharing the same core mechanism.

Toxicity

No lethal dose data exist for TMA-2 in any species, and the toxic dose in humans is unknown.safety citation needed As of the 2003 EMCDDA risk assessment, no toxic effects or deaths had been reported in the EU.^[5] No case reports of serious adverse events or fatalities have appeared in published literature through 2026.

Psychological risks

TMA-2 carries elevated psychological risk compared to mescaline. Effects are highly variable, with a greater-than-average propensity for anxiety, dysphoria, and restlessness.^[3] The long duration extends the window of vulnerability for acute psychological distress.

No systematic evidence exists on persisting perceptual disturbances, psychosis risk, or psychiatric destabilization specific to TMA-2. Class-level evidence from serotonergic psychedelics indicates these risks are rare but real, particularly in individuals with personal or family history of psychotic disorders.

Tolerance and dependence

Tolerance develops rapidly — the serotonin receptors TMA-2 activates reduce in number within 24 hours of a single dose.^[14][15] Full reset takes approximately 7 days.^[15][14]

Cross-tolerance with all classical serotonergic psychedelics — including LSD, psilocybin, mescaline, and other DOx compounds — is expected.^[15] TMA-2 is not habit-forming and produces no physical dependence or withdrawal.

Drug interactions

MAO inhibitors — used for depression and Parkinson's — raise serotonin to dangerous levels when combined with serotonergic drugs. TMA-2's strong serotonin receptor activation could synergize with monoamine oxidase inhibition to produce a dangerous overheating and seizure response.^[16]

SSRIs and SNRIs (common antidepressants) may weaken TMA-2's effects through chronic downregulation, but acute potentiation is also possible — the interaction is bidirectional and unpredictable.^[16]

CYP2D6 substrates — including codeine, tramadol, and certain antidepressants — may be affected because TMA-2 weakly inhibits the liver enzyme that breaks them down.^[13] Clinically relevant interactions are unlikely at typical doses.

Lithium combined with classical psychedelics is flagged as a risk for seizures and unpredictable potentiation.citation needed No TMA-2-specific data exist.

Contraindications

Psychotic disorders and family history of psychosis are absolute contraindications — serotonergic psychedelics can trigger psychotic episodes.inferred

Heart conditions, including high blood pressure, irregular heartbeat, and structural heart disease, are relative contraindications given TMA-2's reported vasoconstriction over its prolonged duration.

Concurrent MAOI use is contraindicated due to serotonin syndrome risk.^[16]

Pregnancy is an absolute contraindication — no reproductive safety data exist.inferred

Seizure disorders are a relative contraindication — phenethylamine psychedelics may lower seizure threshold.inferred

TMA-2 is controlled in most major jurisdictions.^[5]